setrobuvir

Anadys also entered into its first cross-company clinical trial agreement to study setrobuvir in combination with another direct-acting antiviral DAA in healthy volunteers.

unknown title 2011

Anadys was granted U.S. Patent No. 7,939,524, which recognizes the Company's intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds.

unknown title 2011

"Having completed enrollment in the Phase IIb study of setrobuvir with interferon and ribavirin, we have now turned our focus to the implementation of combination studies of setrobuvir with other DAAs," said

unknown title 2011

The $3.9 million increase was primarily attributable to a $3.5 million increase in setrobuvir ANA598 development costs and a $0.7 million increase in ANA773 development costs.

unknown title 2011

Enrollment is complete in the Phase IIb study of setrobuvir ANA598, in which setrobuvir is being tested in combination with pegylated interferon and ribavirin in hepatitis C patients.

unknown title 2011

Anadys is conducting a Phase IIb study of setrobuvir, the Company's DAA, added to pegylated interferon and ribavirin for the treatment of hepatitis C.

unknown title 2011

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, setrobuvir and ANA773.

unknown title 2011

Anadys is conducting a Phase IIb study of setrobuvir, the Company's DAA, added to pegylated interferon and ribavirin for the treatment of hepatitis C.

unknown title 2011

For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that setrobuvir ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.

unknown title 2011

"In addition to the first agreement entered into this past quarter, we are currently taking steps to pursue additional DAA combination studies with setrobuvir in the near-term."

unknown title 2011